Blockchain Registration Transaction Record

Annovis Bio Reports Major Alzheimer's Trial Progress and Promising Biomarker Data

Annovis Bio reports Q3 2025 progress with full Phase 3 Alzheimer's trial activation and promising biomarker data showing reduced inflammation and neurodegeneration for buntanetap therapy.

This development represents a significant advancement in the fight against neurodegenerative diseases that affect millions worldwide. Alzheimer's and Parkinson's diseases currently have limited treatment options, and most available therapies only address symptoms rather than modifying the underlying disease progression. The promising biomarker data showing reductions in inflammation and neurodegeneration suggests buntanetap could potentially slow or halt disease progression, which would represent a breakthrough in neurological treatment. For patients and families affected by these devastating conditions, successful development of disease-modifying therapies could mean preserved cognitive function, maintained independence, and improved quality of life. The progress toward NDA submission also signals potential near-term availability of new treatment options, while the extended patent protection through 2046 ensures long-term commercial viability if approved.